

Market Data

Medigus Ltd.

Nasdaq: MDGS

Fiscal Year	Dec 31
Industry	Diversified
Recent Price	\$0.60
Market Cap	\$14.8M
ADS Out.	24.6M
Avg. Volume (90-day)	104,214
Revenue (FY21)	\$10.1M
Net Income (FY21)	\$4.0M
Cash (YE21)	\$24.0M
Shareholder Equity (YE21)	\$49.0M

Price data as of Sept 16, 2022

[medigus.com](https://www.medigus.com)



Company Overview

An Israeli technology company, Medigus is focused on building innovative growth partnerships, primarily in advanced medical solutions, digital commerce, and electric vehicle (EV) markets.

Medigus' medical-solutions segment includes ownership in Polyrizon Ltd., a clinical development biotech company specializing in the development of innovative nasal gels to provide preventative treatment against a wide range of biological assaults, including COVID-19, and ownership in ScoutCam Inc., a micro- imaging technology company.

Medigus' affiliates in digital commerce include Gix Internet Ltd., a media-tech company, Jeffs' Brands Ltd., a high- growth consumer products company operating primarily on Amazon.com, Safee, a blockchain company focused on NFTs and other digital assets, and Eventer Technologies Ltd., a smart ticketing platform.

In the EV market, the Company's portfolio of technology solution providers includes Charging Robotics Ltd., a wireless robotic charging system for EVs, and Revoltz Ltd., a designer and developer of micro-mobility EVs.

Value Proposition

Medigus and its subsidiaries are developing and advancing innovative solutions for large- scale market applications with a business model designed for maximum flexibility, allowing the Company to develop, commercialize, and support a broad array of new technologies with high growth potential.

The Israeli-based technology company and its subsidiaries are focused on medical- related technologies, internet and other online technologies, and electric vehicle (EV) and wireless EV charging. Medigus began diversifying its operations in 2019, acquiring controlling interests in multiple ventures which should provide long-term shareholder value improvement.

As of December 31, 2021, Medigus' shareholders' equity surpassed \$49 million and in 2021 the Company reported \$4.0 million net income. With approximately \$24 million in cash and cash equivalents and a proven track record of identifying lucrative opportunities, Medigus is ideally positioned to accelerate growth moving forward. Management has proven its ability to act fast, structure deals, and execute. A buyback program, which allows the Company to purchase up to \$3 million of its common stock, launched in the first quarter of 2022, is expected to further improve shareholder value

Key Facts & Metrics



~\$49M

Shareholders' Equity
at year-end 2021



~\$4M

Net Income
in 2021



~\$24M

Cash & Cash Equivalents
at year-end 2021



~\$10.1M

Revenues
in 2021

Investment Highlights

• Operating and investing in large, diverse market segments

- **Online Technologies: Gix Group** (TASE: GIX) – 34.58% ownership in global leader in MarTech solutions with \$45M revenues in 2021 and total addressable market (TAM) of \$345B; **Jeff Brands** (Nasdaq: JFBR) – 35.27% ownership in fast-growing consumer goods company leveraging AI to accelerate sales primarily on Amazon with \$6.5M revenues in 2021 and TAM of \$356B; **Eventer** – 47.69% ownership in smart ticketing and virtual events platform with \$1.4M revenues in 1H22 and a TAM of \$15.7B; **Safee** – signed non-binding MOU for JV focused on trading and monetizing digital assets



JEFFS BRANDS

eventer

Safee

- **EV & Micro Mobility: Charging Robotics** – wholly owned subsidiary revolutionizing EV charging with a TAM of \$827M; **Revoltz** – 19.9% ownership in EV and wireless charging JV with TAM of \$108B; **ParaZero** – 40% ownership in drone safety company that enables global drone deliveries at scale



- **Healthcare: Scoutcam** (OTCQB: SCTC) – 27.02% ownership in innovative visualization technology provider addressing \$16B market opportunity; **Polyrizon** – 37.03% ownership in developer of innovative intranasal products for viral infections, a TAM of \$19.5B; **MUSE System** – patented, FDA approved comprehensive endoscopic device



• Multiple near-term catalysts to drive increasing shareholder value in 2022

- High double-digit revenue growth
- 100% of Gix's revenue will consolidate in 2022
 - *Gix generated \$20M revenue in 1Q22 with \$750K EBITDA*
- Upcoming public listing of Charging Robotics (via reverse merger)
- Filed motion with regulatory authorities to approve \$1.6M dividend distribution
- Planned IPO of Eventer subsidiary